Ergocalciferol
Pro Research Analysisby 
Searched over 200M research papers for "ergocalciferol"
Ergocalciferol Supplementation: Efficacy in Vitamin D Deficiency
Ergocalciferol (vitamin D2) is widely used to treat vitamin D deficiency and insufficiency. Studies in adults and elderly populations show that high-dose ergocalciferol regimens, such as 50,000 IU three times weekly for four weeks, can effectively and safely normalize serum 25-hydroxyvitamin D levels without causing toxicity or adverse effects 35. Regimens totaling at least 600,000 IU over several weeks are particularly effective in achieving vitamin D sufficiency in adults . In nursing home residents, this approach rapidly corrects low vitamin D status, though it does not appear to improve ambulation, cognition, or behavior .
Ergocalciferol in Chronic Kidney Disease (CKD) and Mineral Bone Disorders
In children with CKD stages 2–4, ergocalciferol supplementation delays the onset of secondary hyperparathyroidism and helps achieve normal vitamin D levels, especially in earlier CKD stages, with no significant adverse events . In adults with CKD stages 3–5, ergocalciferol increases 25-hydroxyvitamin D levels and is as effective and safe as calcitriol for managing mineral and bone disorders, with no significant differences in maintaining target calcium, phosphorus, or parathyroid hormone levels . However, in hemodialysis patients, while ergocalciferol raises vitamin D levels, it does not reduce the need for erythropoietin or improve other clinical outcomes .
Ergocalciferol and Cardiovascular or Endothelial Function
Animal studies suggest ergocalciferol can improve endothelial vasodilatory and vasoconstrictor function in mild uraemia, indicating a possible direct benefit on vascular health independent of blood pressure or bone mineral parameters . However, in human trials, ergocalciferol supplementation does not affect renin–angiotensin system activity or lower blood pressure in vitamin D-deficient, overweight individuals .
Ergocalciferol in Type 1 Diabetes
In youth with newly diagnosed type 1 diabetes, ergocalciferol supplementation significantly increases vitamin D levels and reduces serum TNF-α, an inflammatory marker. While it does not significantly change insulin requirements or C-peptide levels, it slows the rise in HbA1c and insulin dose–adjusted HbA1c, suggesting some protection of residual β-cell function and partial clinical remission .
Formulation and Stability of Ergocalciferol
Microencapsulation of ergocalciferol using optimized emulsification techniques achieves high encapsulation efficiency and stability, even under high temperature and humidity, supporting its use in food and pharmaceutical applications .
Ergocalciferol Versus Cholecalciferol (Vitamin D3)
There is ongoing debate about the equivalence of ergocalciferol (D2) and cholecalciferol (D3). Evidence indicates that vitamin D3 is more potent and effective at raising serum 25-hydroxyvitamin D levels, has better binding to vitamin D binding protein, and a longer shelf life compared to D2. Some experts argue that ergocalciferol should not be considered equivalent to cholecalciferol for supplementation or fortification purposes .
Conclusion
Ergocalciferol is effective for correcting vitamin D deficiency and managing certain complications in CKD and type 1 diabetes, with a good safety profile in both children and adults. However, its efficacy may be lower than cholecalciferol, and it does not appear to impact blood pressure or erythropoietin needs in specific populations. Advances in formulation improve its stability, but the choice between D2 and D3 remains important for optimal clinical outcomes.
Sources and full results
Most relevant research papers on this topic
Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial.
Ergocalciferol supplementation effectively delays the development of secondary hyperparathyroidism in children with CKD stages 2-4.
Ergocalciferol in New-onset Type 1 Diabetes: A Randomized Controlled Trial
Ergocalciferol supplementation significantly reduces serum TNF- concentration and the rate of increase in A1c and IDAA1c, suggesting protection of residual -cell function and partial clinical remission in youth with newly diagnosed type 1 diabetes.
EVALUATION OF VITAMIN D REPLETION REGIMENS TO CORRECT VITAMIN D STATUS IN ADULTS
At least 600,000 IU of ergocalciferol is the most effective regimen for achieving vitamin D sufficiency in healthy adults without vitamin D toxicity.
DOI